Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
Conclusions Olaparib in combination with carboplatin and/or paclitaxel resulted in increased hematologic toxicities, making it challenging to establish a dosing regimen that could be tolerated for multiple cycles without dose modifications.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Hematology | Investigational New Drugs | Study | Thrombocytopenia | Toxicology